Alkermes CMO sells 9,000 shares, exercises options
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an exercise-and-sale transaction in company stock.
Rhea-AI Filing Summary
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 5,000 Ordinary Shares at $19.34 per share and sold 9,000 Ordinary Shares in an open-market transaction at a weighted average price of $41.6715 per share.
Both the option exercise and the share sale were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025, meaning they were pre-arranged. The sale price reflects multiple trades between $41.37 and $42.19. After these transactions, Hopkinson directly holds 77,389 Ordinary Shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Hopkinson Craig C.
Role
EVP R&D, Chief Medical Officer
Sold
9,000 shs ($375K)
Approx. gross sale proceeds
$375K
Approx. exercise cost
$97K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) | 5,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 5,000 | $19.34 | $97K |
| Sale | Ordinary Shares | 9,000 | $41.6715 | $375K |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 6,356 contracts (Direct);
Ordinary Shares — 77,389 shares (Direct)
Footnotes (4)
- F1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
- F2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.37 to $42.19. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
- F4. These options are fully vested in accordance with their terms.
Key Figures
Shares sold: 9,000 shares
Weighted average sale price: $41.6715 per share
Options exercised: 5,000 shares
+4 more
7 metrics
Shares sold
9,000 shares
Ordinary Shares sold in open-market transaction on June 1, 2026
Weighted average sale price
$41.6715 per share
Ordinary Shares sale, trades from $41.37 to $42.19
Options exercised
5,000 shares
Employee Stock Option exercise into Ordinary Shares
Option exercise price
$19.34 per share
Exercise price for Employee Stock Option (Right to Buy)
Post-transaction holdings
77,389 shares
Ordinary Shares directly owned after reported transactions
Net share change from trades
9,000 shares net sold
NetBuySellShares from transaction summary
10b5-1 plan adoption date
March 14, 2025
Date reporting person adopted Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, Employee Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Stock Option (Right to Buy) financial
"security_title": "Employee Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Alkermes (ALKS) executive Craig Hopkinson report?
Craig Hopkinson reported exercising options for 5,000 Alkermes Ordinary Shares and selling 9,000 shares. The sale was an open-market transaction at a weighted average price of $41.6715 per share, executed under a pre-arranged Rule 10b5-1 trading plan.
What stock options did Craig Hopkinson exercise in the Alkermes (ALKS) Form 4?
He exercised Employee Stock Options for 5,000 Alkermes Ordinary Shares at an exercise price of $19.34 per share. The filing notes these options are fully vested and the exercise was executed pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
Were Craig Hopkinson’s Alkermes (ALKS) transactions under a Rule 10b5-1 plan?
Yes. The Form 4 states both the option exercise and the 9,000-share sale were effected under a Rule 10b5-1 trading plan adopted on March 14, 2025. Such plans schedule trades in advance, reducing the significance of short-term market timing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
